Voyager Therapeutics (VYGR) Revenue (2015 - 2026)

Voyager Therapeutics has disclosed Revenue across 12 years of filings, most recently posting $3.2 million for Q2 2026.

• In Q2 2026, Revenue fell 38.46% year-over-year to $3.2 million; the TTM figure through Jun 2026 stood at $34.5 million (down 18.94% YoY), while the FY2025 annual figure was $40.4 million, down 49.53% from the prior year.
• Revenue came in at $3.2 million for Q2 2026 at Voyager Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $150.5 million in Q1 2023 to a low of -$1.5 million in Q4 2022.
• Average Revenue over 5 years is $23.2 million, with a median of $6.4 million recorded in 2024.
• Year-over-year, Revenue tumbled 105.52% in 2022 and surged 22769.3% in 2023.
• Over 5 years, Revenue stood at -$1.5 million in 2022, then jumped by 5910.39% to $90.1 million in 2023, then slumped by 93.03% to $6.3 million in 2024, then jumped by 144.28% to $15.3 million in 2025, then plunged by 79.13% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $3.2 million in Q2 2026, $2.6 million in Q1 2026, and $15.3 million in Q4 2025.